Acorda Therapeutics Revenue 2010-2022 | ACOR
Acorda Therapeutics revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Acorda Therapeutics Annual Revenue
(Millions of US $) |
| 2022 |
$119 |
| 2021 |
$129 |
| 2020 |
$153 |
| 2019 |
$192 |
| 2018 |
$471 |
| 2017 |
$588 |
| 2016 |
$520 |
| 2015 |
$493 |
| 2014 |
$401 |
| 2013 |
$336 |
| 2012 |
$306 |
| 2011 |
$292 |
| 2010 |
$191 |
| 2009 |
$55 |
Acorda Therapeutics Quarterly Revenue
(Millions of US $) |
| 2022-12-31 |
$31 |
| 2022-09-30 |
$34 |
| 2022-06-30 |
$31 |
| 2022-03-31 |
$23 |
| 2021-12-31 |
$37 |
| 2021-09-30 |
$31 |
| 2021-06-30 |
$32 |
| 2021-03-31 |
$29 |
| 2020-12-31 |
$38 |
| 2020-09-30 |
$53 |
| 2020-06-30 |
$34 |
| 2020-03-31 |
$28 |
| 2019-12-31 |
$50 |
| 2019-09-30 |
$48 |
| 2019-06-30 |
$50 |
| 2019-03-31 |
$44 |
| 2018-12-31 |
$69 |
| 2018-09-30 |
$143 |
| 2018-06-30 |
$153 |
| 2018-03-31 |
$106 |
| 2017-12-31 |
$188 |
| 2017-09-30 |
$141 |
| 2017-06-30 |
$139 |
| 2017-03-31 |
$119 |
| 2016-12-31 |
$141 |
| 2016-09-30 |
$136 |
| 2016-06-30 |
$127 |
| 2016-03-31 |
$116 |
| 2015-12-31 |
$131 |
| 2015-09-30 |
$148 |
| 2015-06-30 |
$114 |
| 2015-03-31 |
$100 |
| 2014-12-31 |
$118 |
| 2014-09-30 |
$106 |
| 2014-06-30 |
$97 |
| 2014-03-31 |
$81 |
| 2013-12-31 |
$93 |
| 2013-09-30 |
$85 |
| 2013-06-30 |
$87 |
| 2013-03-31 |
$72 |
| 2012-12-31 |
$81 |
| 2012-09-30 |
$77 |
| 2012-06-30 |
$76 |
| 2012-03-31 |
$71 |
| 2011-12-31 |
$73 |
| 2011-09-30 |
$93 |
| 2011-06-30 |
$65 |
| 2011-03-31 |
$61 |
| 2010-12-31 |
$67 |
| 2010-09-30 |
$64 |
| 2010-06-30 |
$43 |
| 2010-03-31 |
$18 |
| 2009-12-31 |
$14 |
| 2009-09-30 |
$15 |
| 2009-06-30 |
$13 |
| 2009-03-31 |
$12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.014B |
$0.119B |
|
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
|
